Quick answer: Cagrilintide is a lipidated amylin analog that acts on amylin and calcitonin receptors. Tirzepatide is a lipidated, GIP-based peptide that acts on the GIP and GLP-1 receptors. They share a half-life strategy but not a target, so they are not interchangeable. A certificate for either should confirm identity by mass, including the lipid. All materials are for laboratory research use only.
Two metabolic-research peptides that act on different receptors
Cagrilintide and tirzepatide are often named in the same sentence because both are long-acting, lipid-modified peptides that appear in metabolic research. That is where the similarity ends. They come from different peptide families, bind different receptors and are studied for different reasons. Searching for one frequently surfaces the other, so buyers and researchers regularly ask whether they are alternatives, complements or simply unrelated.
This guide compares them on origin, structure, receptor targets, the way the published literature describes their duration, and the analytical checks a certificate should support. Everything here is background for laboratory research use only. Nothing in it describes a benefit or a use in people or animals. For single-compound background, see the cagrilintide research overview and the tirzepatide research overview.
Origin: an amylin analog and a dual incretin agonist
Cagrilintide is an analog of amylin, a 37-residue hormone that is co-secreted with insulin from pancreatic beta cells. Native amylin aggregates readily and is cleared quickly, which makes it hard to use as a research tool. Cagrilintide was engineered to resist both problems: sequence changes borrowed in part from the rat sequence and from pramlintide reduce aggregation, and a lipid chain attached to a lysine side chain promotes reversible binding to albumin, which slows clearance. The design work was described by Kruse and colleagues in 2021. A closer look at the older amylin analog is in cagrilintide vs. pramlintide.
Tirzepatide belongs to a different family. It is a 39-residue peptide built on the sequence of glucose-dependent insulinotropic polypeptide (GIP), modified so that it also activates the receptor for glucagon-like peptide-1 (GLP-1). It contains two non-standard Aib (alpha-aminoisobutyric acid) residues that protect against enzymatic cleavage, a C-terminal amide, and a C20 fatty diacid attached through a short linker to a lysine, which again supports albumin binding. Its characterization as an imbalanced and biased dual agonist was published by Willard and colleagues in 2020, and its discovery by Coskun and colleagues in 2018.
The practical point for a buyer is that these are not interchangeable names for one product class. One is an amylin-pathway tool, the other is an incretin-pathway tool. A protocol that names the wrong one tests a different biology.
Side-by-side comparison
| Feature | Cagrilintide | Tirzepatide |
|---|---|---|
| Peptide family | Amylin analog | GIP-based dual incretin agonist |
| Approximate length | 37 residues (amylin-derived) | 39 residues |
| Main receptor targets | Amylin receptors (calcitonin receptor with RAMPs), calcitonin receptor | GIP receptor and GLP-1 receptor |
| Lipid modification | Albumin-binding lipid on a lysine | C20 fatty diacid on a lysine, via linker |
| Non-standard residues | Sequence changes borrowed from rat amylin and pramlintide | Two Aib residues, C-terminal amide |
| Key identity check | Mass of the lipidated form, correct disulfide | Mass of the lipidated form, Aib positions |
| Original description | Kruse et al., 2021 | Coskun et al., 2018; Willard et al., 2020 |
Receptor targets: where each one acts
Amylin signals through receptor complexes made of the calcitonin receptor combined with one of three accessory proteins called RAMPs. Cagrilintide is reported to act on these amylin receptors and also on the calcitonin receptor itself, which is one reason it is described as a dual amylin and calcitonin receptor agonist in some papers.
Tirzepatide acts on two G protein-coupled receptors, the GIP receptor and the GLP-1 receptor. In the cell-based work, it activates the GIP receptor with potency similar to native GIP, while its activity at the GLP-1 receptor is weaker than native GLP-1. It also shows biased signaling, with less recruitment of the arrestin pathway than native GLP-1 at that receptor.
Because the target families do not overlap, results from one compound cannot be read across to the other. That is also the reason the two have been examined together as a pair in separate experimental designs, rather than as substitutes. The wider landscape, including the semaglutide and retatrutide comparisons, is laid out in the four-compound comparison.
Stability and duration in the published work
Both molecules carry a lipid modification intended to extend circulation time, and both were reported in their original papers to have half-lives measured in days rather than minutes in the species studied. The details differ by species and study design, so a single number is not a safe summary. What matters for a buyer is the same in both cases: the lipidated side chain is part of the molecule, and its presence and attachment site are things a good certificate should be able to confirm.
In the lyophilized state, both are handled like other sealed peptide powders: cold, dry and away from light. Once a vial is opened, protocols differ, which is why this guide does not give volumes or concentrations. The handling pages for each compound, cagrilintide storage and tirzepatide storage and stability, cover the general principles.
What a certificate should show for each
A purity percentage by HPLC is the minimum for both, but it is not enough on its own. A lipidated peptide can be made with the wrong lipid, the lipid in the wrong place, or partly without the lipid, and a single main HPLC peak may not reveal that. The more useful questions are about identity. Does the report name the exact compound? Does it show a measured mass that matches the expected mass for the lipidated form, not just the bare backbone? Is the test date and a lot identifier shown, and does it match the vial?
Buyers should also look for an endotoxin result and a sterility statement when the material is meant for cell-based work. For background on reading these documents, see understanding HPLC purity and how to read a COA. The specific purity pages are cagrilintide purity testing and tirzepatide purity testing.
V8 Peptides publishes certificates only for some products, and those certificates report HPLC purity and identity, endotoxin and PCR sterility. This guide describes general buyer practice, not a statement about any particular lot. Product listings are at cagrilintide and tirzepatide.
Choosing between them for a research design
The decision usually starts from the question being asked. A design built around the amylin and calcitonin receptor family points to cagrilintide. A design built around GIP and GLP-1 receptor signaling points to tirzepatide. Designs that compare the two pathways need both, each with its own certificate and its own controls. If a design compares a modified peptide against a native one, the native reference should be sourced separately and documented the same way.
Whatever the choice, record the compound name, the lot, the date the vial was opened and the storage conditions in the lab notebook. Two vials of the same name from different suppliers are not guaranteed to behave the same, and lipidated peptides are among the least forgiving molecules in this respect.
Frequently asked questions
Are cagrilintide and tirzepatide the same kind of peptide?
No. Cagrilintide is an amylin analog and tirzepatide is a GIP-based dual agonist of the GIP and GLP-1 receptors. They have different sequences and different targets.
Which receptors does cagrilintide act on?
The published work describes activity at amylin receptors, which are formed by the calcitonin receptor and an accessory RAMP protein, and at the calcitonin receptor.
Which receptors does tirzepatide act on?
The GIP receptor and the GLP-1 receptor. In cell studies its GIP receptor activity resembles native GIP, and its GLP-1 receptor activity is weaker than native GLP-1.
Why do both have a lipid chain?
The lipid supports reversible binding to albumin, which slows clearance in the species studied. It is part of the molecule, so a certificate should confirm it.
Can an HPLC purity number confirm the lipid is attached?
Not reliably. Identity by measured mass is the better check, because the lipidated and bare forms differ in mass.
Can I swap one for the other in a protocol?
No. They test different pathways, so swapping them changes the question, not just the reagent.
Does V8 sell both?
Yes, both are listed for laboratory research use only.
Does this article describe a use in people?
No. It summarizes published preclinical and structural work. Neither compound is sold here for human or animal consumption.
How should the lyophilized powder be stored?
Sealed, cold, dry and away from light. Note the date any vial is opened.
What should I record for each vial?
The exact compound name, lot identifier, certificate date, supplier and storage conditions.
References
- Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.
- Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.